Cite

HARVARD Citation

    Harb, W. et al. (n.d.). 42OA phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas. Annals of oncology. p. . [Online]. 
  
Back to record